Overview

A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872

Status:
Completed
Trial end date:
2017-05-30
Target enrollment:
Participant gender:
Summary
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Alios Biopharma Inc.
Treatments:
Digoxin
Midazolam
Oseltamivir
Pitavastatin